Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers

Dominik Glodzik, Ana Bosch, Johan Hartman, Mattias Aine, Johan Vallon-Christersson, Christel Reuterswärd, Anna Karlsson, Shamik Mitra, Emma Niméus, Karolina Holm, Jari Häkkinen, Cecilia Hegardt, Lao H. Saal, Christer Larsson, Martin Malmberg, Lisa Rydén, Anna Ehinger, Niklas Loman, Anders Kvist, Hans Ehrencrona, Serena Nik-Zainal, Åke Borg and Johan Staaf ()
Additional contact information
Dominik Glodzik: Lund University, Medicon Village
Ana Bosch: Lund University, Medicon Village
Johan Hartman: Department of Oncology and Pathology, Karolinska Institute
Mattias Aine: Lund University, Medicon Village
Johan Vallon-Christersson: Lund University, Medicon Village
Christel Reuterswärd: Lund University, Medicon Village
Anna Karlsson: Lund University, Medicon Village
Shamik Mitra: Lund University, Medicon Village
Emma Niméus: Lund University, Medicon Village
Karolina Holm: Lund University, Medicon Village
Jari Häkkinen: Lund University, Medicon Village
Cecilia Hegardt: Lund University, Medicon Village
Lao H. Saal: Lund University, Medicon Village
Christer Larsson: Lund University, Medicon Village
Martin Malmberg: Skåne University Hospital
Lisa Rydén: Lund University
Anna Ehinger: Lund University, Medicon Village
Niklas Loman: Lund University, Medicon Village
Anders Kvist: Lund University, Medicon Village
Hans Ehrencrona: Department of Genetics and Pathology, Laboratory Medicine, Region Skåne
Serena Nik-Zainal: The Clinical School University of Cambridge
Åke Borg: Lund University, Medicon Village
Johan Staaf: Lund University, Medicon Village

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract Homologous recombination deficiency (HRD) is a defining characteristic in BRCA-deficient breast tumors caused by genetic or epigenetic alterations in key pathway genes. We investigated the frequency of BRCA1 promoter hypermethylation in 237 triple-negative breast cancers (TNBCs) from a population-based study using reported whole genome and RNA sequencing data, complemented with analyses of genetic, epigenetic, transcriptomic and immune infiltration phenotypes. We demonstrate that BRCA1 promoter hypermethylation is twice as frequent as BRCA1 pathogenic variants in early-stage TNBC and that hypermethylated and mutated cases have similarly improved prognosis after adjuvant chemotherapy. BRCA1 hypermethylation confers an HRD, immune cell type, genome-wide DNA methylation, and transcriptional phenotype similar to TNBC tumors with BRCA1-inactivating variants, and it can be observed in matched peripheral blood of patients with tumor hypermethylation. Hypermethylation may be an early event in tumor development that progress along a common pathway with BRCA1-mutated disease, representing a promising DNA-based biomarker for early-stage TNBC.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17537-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17537-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17537-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().